Please assess the completion status of the following clinical trial:

Trial Title: MANP in Hypertension and Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertension defined as 140 mmHg ≤ systolic BP ≤ 180 mmHg or 90 mmHg ≤ diastolic BP ≤ 100 mmHg despite anti-hypertensive medical therapy~* Metabolic Syndrome defined as the presence of any two of the following traits:~* Abdominal obesity, defined as a waist circumference in men ≥102 cm (40 in) and in women ≥88 cm (35 in)~* Serum triglycerides ≥150 mg/dL (1.7 mmol/L)~* Serum HDL cholesterol \<40 mg/dL (1 mmol/L) in men and \<50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL cholesterol~* Fasting plasma glucose ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose~* Between the ages of 18 and 75 years~* Use of antihypertensive medications at a stable dose for 30 days preceding screening visit.~* Use of statins or ezetimibe or combinations on stable dose for 60 days preceding screening visit.~Exclusion Criteria:~* Known hypersensitivity or allergy to MANP or its components, carperitide, other natriuretic peptides, or related compounds;~* Subjects with orthostatic hypotension at the screening visit, defined as a decrease in systolic BP of \>20 mmHg or a decrease in diastolic BP of \>10 mmHg within three minutes of standing when compared with blood pressure from the sitting position.~* Subjects with a systolic BP \>180 mmHg or a diastolic BP \>100 mmHg~* Women of child-bearing potential~* The presence of abnormal laboratory values at screening visit considered clinically significant by the Investigator. Specifically they will be excluded if a) Serum sodium of \< 135 mEq/dL or \> 145 mEq/dL; b) Serum potassium of \< 3.5 mEq/dL or \> 5.1 mEq/dL~* Subjects whose body weight has changed more than 3% in the last 3 months~* Having received any investigational drug or device within 30 days prior to entry into the study;~* A history (within the last 2 years) of alcohol risky use (defined as more than 14 standard drinks per week on average or more than 4 drinks on any day for men under age 65 - defined as more than 7 standard drinks per week on average or more than 3 drinks on any day for women and adults 65 years and older);~* A history of illicit drug use, psychiatric illness that might impair the participation to the study, physical dependence to any opioid, or any history of substance abuse or addiction;~* A history of difficulty with donating blood or donated blood or blood products within 45 days prior to enrollment;~* Clinically significant new illness in the 1 month before screening in the opinion of the Investigator;~* History of severe allergies;~* History of coronary artery disease or cerebrovascular disease or syncope;~* History of epilepsy or other seizure disorder;~* History of organ transplantation;~* Malignancy within 5 years of the screening visit (with the exception of basal cell and squamous cell skin carcinoma);~* Clinically significant intrinsic renal disease, renal artery stenosis, or history of fibromuscular dysplasia of the renal arteries;~* Consumption of a phosphodiesterase-5 inhibitor (sildenafil, vardenafil, or tadalafil) within 72 hours of receiving MANP.~* Episodic or chronic use of nitrates (Isordil, nitroglycerine), MAO inhibitors, antipsychotics, antiarrhythmics, psychostimulants, systemic corticosteroids, cholestyramine and cholestipol reisins, fibrates, nicotinic acid, cyclosporin, rifampin or other highly potent PgP inhibitors.~* Any disease or condition (medical or surgical) which, in the opinion of the investigator, might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk.~* Subjects who smoke or have any history of tobacco product use more recently than 6 months prior to the enrollment into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MANP (Type: EXPERIMENTAL): subjects receiving MANP (2.5 micrograms/kg, single subcutaneous injection)
- Placebo (Type: PLACEBO_COMPARATOR): subjects receiving placebo (saline solution, single subcutaneous injection)

Based on this trial design, predict the completion outcome and termination type (if applicable).